Clinical trials: Allergy; Dermatitis
Severe Uncontrolled Atopic Dermatitis
Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)
Provide pre-approval single patient Expanded Access (compassionate use) of abrocitinib for patients with severe uncontrolled atopic dermatitis
- Trial name
- NCT05466578
- Testing
- abrocitinib
- Sponsor
- Pfizer
Atopic Dermatitis
HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
This study is a randomized, double-blind, placebo-controlled, multicenter Phase Ib/II clinical study designed to evaluate the efficacy, safety, and PK characteristics of HL-300 ointment with different concentration regimens for…
- Trial name
- NCT07629778
- Testing
- HL-300
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Atopic Dermatitis
Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis
The study is to reflect the effectiveness and safety of MG-K10 humanized monoclonal antibody injection in patients with moderate to severe atopic dermatitis.administered every 4 weeks for 52 week
- Trial name
- NCT06026891
- Where
- China
- Volunteers
- 498 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Dermatitis, Atopic
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis
this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe atopic dermatitis.
- Trial name
- NCT02595008
- Testing
- DSXS
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Dermatitis, Atopic
Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis
Purpose of the study: One bothering feature of atopic dermatitis is its relapsing nature. Hence, it is worthwhile to test modes how to efficiently prevent relapses or at least increase the time until the disease recurs.
- Trial name
- NCT00185510
- Testing
- Methylprednisolone Aceponate (Advantan, BAY86-4862)
- Volunteers
- 250 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01859988
- Testing
- Dupilumab
- Where
- 84 sites in United States, Canada and 5 more
- Volunteers
- 380 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Dose-Finding Study of M516102 in the Treatment of Pruritus Associated With Atopic Dermatitis
This study is to investigate the efficacy and safety of M516102 and to evaluate the dose response relationship of M516102 and placebo, in the treatment of pruritus associated with atopic dermatitis.
- Trial name
- NCT00980629
- Testing
- M516102
- Where
- 4 sites in France, Germany and 2 more
- Sponsor
- Maruho Co., Ltd.
Atopic Dermatitis
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
- Trial name
- Measure Up 1 (NCT03569293)
- Testing
- Upadacitinib
- Where
- 180 sites in United States, Argentina and 23 more
- Volunteers
- 912 people
- Sponsor
- AbbVie
Atopic Dermatitis
Methodological Study of the Effect of a Lotion Containing Nature Based Microbial Extract on Atopic Skin
The purpose of the study is to test the selected methods and to explore the effect of nature-based exposure on immunological biomarkers and the condition of atopic skin.
- Trial name
- NCT06499766
- Testing
- Biodiversity intervention by inactivated microbial extract
- Where
- Finland
- Volunteers
- 12 people
- Sponsor
- Uute Scientific Oy
Atopic Dermatitis
Quality of Life Study in Adults With Facial Eczema
This study is not being conducted in the US. The study consists of a 4 week double blind treatment period. All patients meeting the inclusion/exclusion criteria will enter the study at day 0 and be randomized into either…
- Trial name
- NCT00120302
- Testing
- Pimecrolimus
- Where
- United Kingdom
- Volunteers
- 76 people
- Sponsor
- Novartis
Eczema, Atopic
The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema
This is a double blind, randomised, non-clinical study with 2 groups (1 investigational group and 1 comparator group) aiming to assess the effectiveness of PEA for reducing eczema severity compared to a base comparator…
- Trial name
- NCT05003453
- Testing
- 1.5% Palmitoylethanolamide (PEA) sold as Levagen+
- Where
- Australia
- Volunteers
- 72 people
- Sponsor
- RDC Clinical Pty Ltd
Dermatitis, Atopic
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Mepolizumab is a humanized Immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that acts on Interleukin-5 (IL-5), which is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils…
- Trial name
- NCT03055195
- Testing
- Mepolizumab 100 mg
- Where
- 20 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis…
- Trial name
- NCT06808477
- Testing
- BBT001
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 237 people, healthy volunteers welcome
- Sponsor
- Bambusa Therapeutics
Atopic Dermatitis
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
This is a first-in-human, randomized, double-blind, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, tolerability, and PK of ATI-1777 solution following twice-daily applications to target areas of…
- Trial name
- NCT04598269
- Testing
- ATI-1777, Vehicle
- Where
- 14 sites in United States
- Volunteers
- 50 people
- Sponsor
- Aclaris Therapeutics, Inc.
Allergic Contact Dermatitis
Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis
The purpose of this study is to evaluate the safety and efficacy of EB01 Cream (0.2%, 1.0%, 2.0%) applied twice per day (BID) for the treatment of moderate to severe chronic allergic contact dermatitis (ACD).
- Trial name
- NCT03680131
- Testing
- EB01 Cream 0.2%, EB01 Cream 1.0%, EB01 Cream 2.0%
- Where
- 15 sites in United States, Canada
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- Edesa Biotech Inc.
Atopic Dermatitis
Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting
An open-label, multicenter study, of long term management to evaluate effectiveness, tolerability and safety of pimecrolimus cream 1% in pediatric patients with mild to moderate atopic dermatitis in a daily practice
- Trial name
- NCT00509990
- Testing
- Pimecrolimus
- Where
- 6 sites in Mexico, Venezuela
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.
- Trial name
- BREEZE-AD-PEDS (NCT03952559)
- Testing
- Baricitinib, Topical corticosteroid
- Where
- 78 sites in Argentina, Australia and 15 more
- Volunteers
- 516 people
- Sponsor
- Eli Lilly and Company
Dermatitis Atopic
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live…
- Trial name
- HYDRO (NCT06015308)
- Testing
- Amlitelimab, Tdap vaccine, PPS vaccine
- Where
- 57 sites in United States, Canada
- Volunteers
- 224 people
- Sponsor
- Sanofi
Moderate-to-severe Atopic Dermatitis
A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis
This study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of CBP-201 in adult subjects with moderate to severe atopic dermatitis.
- Trial name
- NCT04444752
- Testing
- CBP-201
- Where
- 59 sites in United States, Australia and 2 more
- Volunteers
- 226 people
- Sponsor
- Connect Biopharm LLC
Moderate-to-Severe Atopic Dermatitis
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…
- Trial name
- NCT03989349
- Testing
- Nemolizumab
- Where
- 138 sites in United States, Belgium and 9 more
- Volunteers
- 787 people
- Sponsor
- Galderma R&D
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.